Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer

Breast Cancer

Volumn 23, Issue 1, 2016, Pages 120-127

  Shiomi Mouri, Yukako ^a   Kousaka, Junko ^a   Ando, Takahito ^a   Tetsuka, Rie ^a   Nakano, Shogo ^a   Yoshida, Miwa ^a   Fujii, Kimihito ^a   Akizuki, Miwa ^a   Imai, Tsuneo ^a   Fukutomi, Takashi ^a   Kobayashi, Katsumasa ^b  

^a AICHI MEDICAL UNIVERSITY   (Japan)

^b Sakura Hospital   (Japan)

Author keywords

Breast cancer; CA15 3; CEA; CTC; Tumor marker

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; TUMOR MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; MUCIN 1; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ANTIGEN DETECTION; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER PROGNOSIS; CANCER SURVIVAL; CELL COUNT; CELL MEMBRANE PERMEABILITY; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; BREAST TUMOR; CANCER GRADING; LUNG CARCINOMA; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SECONDARY; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL COUNT; FEMALE; HUMANS; MIDDLE AGED; MUCIN-1; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84954197536     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-014-0539-x     Document Type: Article

References (23)

1. Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the cell search system in patients with metastatic breast colorectal and prostate cancer. J Oncol. 2010;2010:617421.
2. Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P, et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol. 2010;21:729–33.
3. Fehm T, Sauerbrei W. Information from CTC measurements for metastatic breast cancer prognosis-we should do more than selecting an “optimal cut point”. Breast Cancer Res Treat. 2010;122:219–20.
4. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12:4218–24.
5. Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol. 2009;33:315–8.
6. Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis C, Apostolaki S, et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol. 2002;20:3404–12.
7. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol. 2006;24:3756–62.
8. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.
9. Martin M, Garcia-Saenz JA, Maestro De las Casas ML, Vidaurreta M, Puente J, Veganzones S, et al. Circulating tumor cells in metastatic breast cancer: timing of blood extraction for analysis. Anticancer Res. 2009;29:4185–7.
10. Ramirez JM, Fehm T, Orsini M, Cayrefourcq L, Maudelonde T, Pantel K, et al. Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients. Clin Chem. 2014;60:214–21.
11. Kaiser J. Medicine. Cancer’s circulation problem. Science. 2010;327:1072–4.
12. Kallergi G, Konstantinidis G, Markomanolaki H, Papadaki MA, Mavroudis D, Stournaras C, et al. Apoptotic circulating tumor cells in early and metastatic breast cancer patients. Mol Cancer Ther. 2013;12:1886–95.
13. Pierga JY, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol. 2012;23:618–24.
14. Giordano A, Egleston BL, Hajage D, Bland J, Hortobagyi GN, Reuben JM, et al. Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients. Clin Cancer Res. 2013;19:1596–602.
15. Babayan A, Hannemann J, Spotter J, Muller V, Pantel K, Joosse SA. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS ONE. 2013;8:e75038.
16. Roop RP, Naughton MJ, Van Poznak C, Schneider JG, Lammers PE, Pluard TJ, et al. A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancer. Clin Breast Cancer. 2013;13:409–15.
17. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, et al. Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006;12:6403–9.
18. Friedlander TW, Premasekharan G, Paris PL. Looking back, to the future of circulating tumor cells. Pharmacol Ther. 2013. doi:10.1016/j.pharmthera.2013.12.011.
19. Chimonidou M, Kallergi G, Georgoulias V, Welch DR, Lianidou ES. Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells. Mol Cancer Res. 2013;11:1248–57.
20. Botteri E, Sandri MT, Bagnardi V, Munzone E, Zorzino L, Rotmensz N, et al. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. Breast Cancer Res Treat. 2010;122:211–7.
21. Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol. 2009;27:5153–9.
22. Nakamura S, Yagata H, Ohno S, Yamaguchi H, Iwata H, Tsunoda N, et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer. 2010;17:199–204.
23. Braun S, Hepp F, Kentenich CR, Janni W, Pantel K, Riethmuller G, et al. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res. 1999;5:3999–4004.